Experimentally, overexpression of PDGFA and PDGFRA successfully induces GBM development in mouse models.22–25 These results suggest critical roles of PDGFRA in GBM and identify PDGFA/PDGFRA axis as a potential therapeutic target for GBM.16 Indeed, several anti-tumor agents targeting PDGFRA have been developed, such as Imatinib (Gleevec®), Sorafenib (Nexavar®), Nilotinib (Tasigna®), and Sunitinib (Sutent®). This evidence concerns the gene PDGFRA and neoplasm.